Neurokinin-1 Receptor as a potential drug target for COVID-19 treatment

McGonagle, 2020, The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease, Autoimmun. Rev., 19, 10.1016/j.autrev.2020.102537 WHO, Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020, 2020. Zheng, 2020, Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha, Eur. Rev. Med. Pharmacol. Sci., 24, 3404 B. insider, A day-by-day breakdown of coronavirus symptoms shows how the disease COVID-19 goes from bad to worse. https://www.businessinsider.com/coronavirus-covid19-day-by-day-symptoms-patients-2020–2, 2020. Lindsey, 2020, Covid-19 — the search for effective therapy, N. Eng. J. Med. US, 1931, An unidentified depressor substance in certain tissue extracts, J. Physiol., 72, 74, 10.1113/jphysiol.1931.sp002763 S. Graefe, S.S. Mohiuddin, Biochemistry, Substance P, in StatPearls, 2020: Treasure Island (FL). Cuello, 1979, Detection of substance P in the central nervous system by a monoclonal antibody, Proc. Natl. Acad. Sci. USA, 76, 3532, 10.1073/pnas.76.7.3532 Ho, 1997, Human monocytes and macrophages express substance P and neurokinin-1 receptor, J. Immunol., 159, 5654, 10.4049/jimmunol.159.11.5654 Chernova, 2009, Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R), J. Leukoc. Biol., 85, 154, 10.1189/jlb.0408260 O’Connor, 2004, The role of substance P in inflammatory disease, J. Cell Physiol., 201, 167, 10.1002/jcp.20061 Saito, 1991, Pharmacological properties of the tachykinin receptor subtype in the endothelial cell and vasodilation, Ann. N. Y. Acad. Sci., 632, 457, 10.1111/j.1749-6632.1991.tb33155.x Mazzone, 2000, Respiratory actions of tachykinins in the nucleus of the solitary tract: effect of neonatal capsaicin pretreatment, Br. J. Pharmacol., 129, 1132, 10.1038/sj.bjp.0703173 Ramkissoon, 2006, G protein-coupled receptors in haematopoietic disruption, Expert Opin. Biol. Ther., 6, 109, 10.1517/14712598.6.2.109 Bost, 2004, Tachykinin-mediated modulation of the immune response, Front. Biosci., 9, 3331, 10.2741/1484 Mehboob, 2017, Substance P/Neurokinin 1 and trigeminal system: a possible link to the pathogenesis in sudden perinatal deaths, Front. Neurol., 8, 82, 10.3389/fneur.2017.00082 Badri, 2019, Emerging targets for cough therapies; NK1 receptor antagonists, Pulm. Pharmacol. Ther., 59, 10.1016/j.pupt.2019.101853 Smith, 2020, The Neurokinin-1 Receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1), Chest, 157, 111, 10.1016/j.chest.2019.08.001 Otsuka, 2011, Plasma substance P levels in patients with persistent cough, Respiration, 82, 431, 10.1159/000330419 Lavezzi, 2011, Developmental alterations of the spinal trigeminal nucleus disclosed by substance P immunohistochemistry in fetal and infant sudden unexplained deaths, Neuropathology, 31, 405, 10.1111/j.1440-1789.2010.01190.x Hayashi, 2016, Immunohistochemical analysis of brainstem lesions in the autopsy cases with severe motor and intellectual disabilities showing sudden unexplained death, Front. Neurol., 7, 93, 10.3389/fneur.2016.00093 A.C, 2020, Treating COVID-19 - off-label drug use, compassionate use, and randomized clinical trials during pandemics, JAMA, 323, 1897, 10.1001/jama.2020.4742 Devin, 2014, Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition, Hypertension, 63, 951, 10.1161/HYPERTENSIONAHA.113.02767 Kierszenbaum, 2007, An introduction to pathology Touyz, 2020, ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19, Clin. Sci., 134, 747, 10.1042/CS20200363 Zhu, 2018, Correlation between the levels of serum cystatin C and substance P in peripheral blood in diabetes mellitus patients complicated with hypertension, Exp. Ther. Med., 16, 1159 Manak, 2010, Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals, AIDS, 24, 2789, 10.1097/QAD.0b013e3283405c33 Ho, 2004, Substance P and neurokinin-1 receptor modulation of HIV, J. Neuroimmunol., 157, 48, 10.1016/j.jneuroim.2004.08.022 Mashaghi, 2016, Neuropeptide substance P and the immune response, Cell Mol. Life Sci., 73, 4249, 10.1007/s00018-016-2293-z Johnson, 2016, The therapeutic potential of targeting substance P/NK-1R interactions in inflammatory CNS disorders, Front. Cell Neurosci., 10, 296 Marriott, 2001, Substance P receptor mediated macrophage responses, Adv. Exp. Med. Biol., 493, 247, 10.1007/0-306-47611-8_30 Marriott, 1998, Substance P diminishes lipopolysaccharide and interferon-gamma-induced TGF-beta 1 production by cultured murine macrophages, Cell Immunol., 183, 113, 10.1006/cimm.1998.1248 Covas, 1994, Disturbed immunoregulatory properties of the neuropeptide substance P on lymphocyte proliferation in HIV infection, Clin. Exp. Immunol., 96, 384, 10.1111/j.1365-2249.1994.tb06039.x Marriott, 2000, IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages, J. Immunol., 165, 182, 10.4049/jimmunol.165.1.182 Bozic, 1996, Neurogenic amplification of immune complex inflammation, Science, 273, 1722, 10.1126/science.273.5282.1722 Leng, 2020, Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia, Aging Dis., 11, 216, 10.14336/AD.2020.0228 Sarzi-Puttini, 2020, COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?, Clin. Exp. Rheumatol., 38, 337, 10.55563/clinexprheumatol/xcdary Borson, 1985, Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections, J. Appl. Physiol., 66, 2653, 10.1152/jappl.1989.66.6.2653 Song, 2014, Inhibitors of endopeptidase and angiotensin-converting enzyme lead to an amplification of the morphological changes and an upregulation of the substance P system in a muscle overuse model, BMC Musculoskelet. Disord., 15, 126, 10.1186/1471-2474-15-126 Geppetti, 1993, Characterization of tachykinin receptors in ferret trachea by peptide agonists and nonpeptide antagonists, Am. J. Physiol., 265, L164 Nieber, 1992, Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma, J. Allergy Clin. Immunol., 90, 646, 10.1016/0091-6749(92)90138-R Tomaki, 1995, Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis, Am. J. Respir. Crit. Care Med., 151, 613, 10.1164/ajrccm/151.3_Pt_1.613 Adcock, 1993, Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids, J. Mol. Endocrinol., 11, 1, 10.1677/jme.0.0110001 Bertrand, 1996, Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease, Trends Pharmacol. Sci., 17, 255, 10.1016/0165-6147(96)10027-4 Kaczyńska, 2018, Neuropeptides and breathing in health and disease, Pulm. Pharm. Ther., 48, 217, 10.1016/j.pupt.2017.12.001 Szereda-Przestaszewska, 2020, Serotonin and substance P: synergy or competition in the control of breathing, Auton. Neurosci., 225, 10.1016/j.autneu.2020.102658 Bright, 2017, Abnormalities in substance P neurokinin-1 receptor binding in key brainstem nuclei in sudden infant death syndrome related to prematurity and sex, PLoS One, 12, 0184958, 10.1371/journal.pone.0184958 Parameswaran, 2002, Airway hyperresponsiveness and calcium handling by smooth muscle: a “deeper look”, Chest, 121, 621, 10.1378/chest.121.2.621 Mehboob, 2014, Vertebrate specific oncogenic TAC1 has unconventional networking properties, Healthmed, 8, 843 Lorente, 2019, Persistently high serum substance P levels and early mortality in patients with severe traumatic brain injury, World Neurosurg., 132, 613, 10.1016/j.wneu.2019.08.064 Muhammad, 2018, Neurochemical alterations in sudden unexplained perinatal deaths-a review, Front. Pediatr., 6, 6, 10.3389/fped.2018.00006 Mehboob, 2017, Towards better understanding of the pathogenesis of neuronal respiratory network in sudden perinatal death, Front. Neurol., 8, 320, 10.3389/fneur.2017.00320 Mehboob, 2015, Role of neurotransmitter substance P in progression of oral squamous cell carcinoma, Pathol. Res. Pract., 211, 203, 10.1016/j.prp.2014.09.016 Dehlin, 2014, Substance P in heart failure: the good and the bad, Int. J. Cardiol., 170, 270, 10.1016/j.ijcard.2013.11.010 Dehlin, 2013, Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension, Int. J. Cardiol., 168, 4643, 10.1016/j.ijcard.2013.07.190 Widiapradja, 2019, Regulation of cardiac mast cell maturation and function by the Neurokinin-1 Receptor in the fibrotic heart, Sci. Rep., 9, 11004, 10.1038/s41598-019-47369-0 Mistrova, 2016, Role of substance P in the cardiovascular system, Neuropeptides, 58, 41, 10.1016/j.npep.2015.12.005 D’Souza, 2007, Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection, J. Parasitol., 93, 1121, 10.1645/GE-596R1.1 Meléndez, 2011, Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells, Cardiovasc Res., 92, 420, 10.1093/cvr/cvr244 Meléndez, 2019, Substance P as a potential biomarker of pain assessment in dogs, Iran. J. Vet. Res., 20, 289 Caroleo, 2020, Targeting neuropathic pain: pathobiology, current treatment and peptidomimetics as a new therapeutic opportunity, Curr. Med. Chem., 27, 1469, 10.2174/0929867326666190530121133 Zieglgansberger, 2019, Substance P and pain chronicity, Cell Tissue Res., 375, 227, 10.1007/s00441-018-2922-y Han, 2019, Involvement of substance P in the analgesic effect of low-level laser therapy in a mouse model of chronic widespread muscle pain, Pain. Med., 20, 1963, 10.1093/pm/pnz056 Zhang, 2019, Activation of mitogen-activated protein kinases in satellite glial cells of the trigeminal ganglion contributes to substance P-mediated inflammatory pain, Int. J. Oral. Sci., 11, 24, 10.1038/s41368-019-0055-0 Casault, 2019, Cytokine responses in severe traumatic brain injury: where there is smoke, is there fire?, Neurocrit Care, 30, 22, 10.1007/s12028-018-0522-z Wang, 2014, Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy, Asian Pac. J. Cancer Prev., 15, 10045, 10.7314/APJCP.2014.15.23.10045 Okafor, 2017, The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting, J. Anaesthesiol. Clin. Pharmacol., 33, 441, 10.4103/0970-9185.222511 Tuluc, 2014, HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P, J. Leukoc. Biol., 96, 143, 10.1189/jlb.4AB0813-434RR Robinson, 2015, Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis, Biomed. Res. Int., 2015, 10.1155/2015/645153 Robinson, 2009, Substance P is required for the pathogenesis of EMCV infection in mice, Int. J. Clin. Exp. Med., 2, 76 Hamza, 2007, Herpes simplex virus type-1 latency-associated transcript-induced immunoreactivity of substance P in trigeminal neurons is reversed by bone morphogenetic protein-7, Neurosci. Lett., 413, 31, 10.1016/j.neulet.2006.11.063 Bossaller, 1992, In vivo measurement of endothelium-dependent vasodilation with substance P in man, Herz, 17, 284 Dalzell, 2014, Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat, Cardiovasc Ther., 32, 13, 10.1111/1755-5922.12053 Wang, 2011, Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons, PLoS One, 6, 19229, 10.1371/journal.pone.0019229 M.A. Ibrahim, Preuss C.V., Antiemetic Neurokinin-1 Receptor Blockers, in StatPearls 2020: Treasure Island (FL). https://www.ncbi.nlm.nih.gov/books/NBK470394/. Quartara, 2006, Tachykinin receptors antagonists: from research to clinic, Curr. Drug Targets, 7, 975, 10.2174/138945006778019381 Munoz, 2013, Involvement of substance P and the NK-1 receptor in cancer progression, Peptides, 48, 1, 10.1016/j.peptides.2013.07.024 Mehboob, 2020, Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach, MedRxiv Shoenfeld, 2020, Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning, Autoimmun. Rev., 19, 10.1016/j.autrev.2020.102538